Head and Neck Medicine by Alexandros G.Sfakianakis: Treatment optimization with secukinumab 150 mg for moderate-to-severe psoriasis in clinical practice: a single-center open-label 52-week study

Παρασκευή 16 Φεβρουαρίου 2018

Treatment optimization with secukinumab 150 mg for moderate-to-severe psoriasis in clinical practice: a single-center open-label 52-week study

http://ift.tt/2ByAMmN

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου